Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.02 USD | +1.53% | +3.66% | +6.10% |
Apr. 23 | Edwards Lifesciences Corporation: The story continues | |
Apr. 15 | Exact Sciences Names Aaron Bloomer CFO | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+6.10% | 20.89B | C+ | ||
-2.25% | 187B | C+ | ||
-1.32% | 108B | C | ||
-3.92% | 67.71B | A | ||
+7.99% | 53.07B | B- | ||
+15.74% | 47.36B | B- | ||
+6.01% | 39.73B | B+ | ||
+10.81% | 28.56B | A- | ||
+2.34% | 26.55B | B | ||
+15.97% | 25.13B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BAX Stock
- Ratings Baxter International Inc.